Pharsight

Drug Patents Expiring in 2023

1. Akynzeo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6297375 HELSINN HLTHCARE 4-phenyl-pyridine derivatives
Mar, 2023

(11 months ago)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

AKYNZEO family patents

Family Patents

2. Anoro Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

3. Binosto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7964212 ASCEND THERAPS US Effervescent compositions comprising phosphonates and methods related thereto
Mar, 2023

(11 months ago)

US7488496 ASCEND THERAPS US Effervescent compositions comprising bisphosphonates and methods related thereto
Aug, 2023

(6 months ago)

Drugs and Companies using ALENDRONATE SODIUM ingredient

Market Authorisation Date: 12 March, 2012

Treatment: NA

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage

BINOSTO family patents

Family Patents

4. Breo Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44874 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 13, 2026
New Strength (NS) May 13, 2026
Pediatric Exclusivity (PED) Nov 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; For the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including...

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

5. Cabenuva Kit patents expiration

CABENUVA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 21 January, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

Family Patents

6. Complera patents expiration

COMPLERA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(10 months ago)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 August, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage

COMPLERA family patents

Family Patents

7. Coreg Cr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7268156 WOODWARD Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Jun, 2023

(8 months ago)

Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: Treatment of hypertension; Treatment of congestive heart failure

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of COREG CR before it's drug patent expiration?
More Information on Dosage

COREG CR family patents

Family Patents

8. Dexilant patents expiration

DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(1 year, 27 days ago)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; To maintain healing of ee and relief of heartburn; Maintain healing of erosive esophagitis (ee) f...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

9. Dexilant Solutab patents expiration

DEXILANT SOLUTAB's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(1 year, 27 days ago)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents

10. Dificid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8586551 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jul, 2023

(7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 24, 2027

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 27 May, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage

DIFICID family patents

Family Patents

11. Dutrebis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7820660 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(10 months ago)

US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(4 months ago)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 06 February, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

DUTREBIS family patents

Family Patents

12. Edurant patents expiration

EDURANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080551 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2023

(10 months ago)

Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 20 May, 2011

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

EDURANT family patents

Family Patents

13. Eligard Kit patents expiration

ELIGARD KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8470359 TOLMAR THERAP Sustained release polymer
Oct, 2023

(4 months ago)

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 13 February, 2003

Treatment: Method of treating cancer

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

ELIGARD KIT family patents

Family Patents

14. Fensolvi Kit patents expiration

FENSOLVI KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8470359 TOLMAR Sustained release polymer
Oct, 2023

(4 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) May 1, 2023

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 01 May, 2020

Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

FENSOLVI KIT family patents

Family Patents

15. Feraheme patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6599498 COVIS Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
Jun, 2023

(7 months ago)

Drugs and Companies using FERUMOXYTOL ingredient

Market Authorisation Date: 30 June, 2009

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of FERAHEME before it's drug patent expiration?
More Information on Dosage

FERAHEME family patents

Family Patents

16. Halaven patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6214865 EISAI INC Macrocyclic analogs and methods of their use and preparation
Jul, 2023

(7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Sep 13, 2025
Pediatric Exclusivity (PED) Mar 13, 2026

Drugs and Companies using ERIBULIN MESYLATE ingredient

Market Authorisation Date: 15 November, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of HALAVEN before it's drug patent expiration?
More Information on Dosage

HALAVEN family patents

Family Patents

17. Ibrance patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6936612 PFIZER 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
Jan, 2023

(1 year, 1 month ago)

US7208489 PFIZER 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Jan, 2023

(1 year, 1 month ago)

Drugs and Companies using PALBOCICLIB ingredient

Market Authorisation Date: 03 February, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage

IBRANCE family patents

Family Patents

18. Injectafer patents expiration

INJECTAFER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11590097 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(4 months ago)

US11123321 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(4 months ago)

US9376505 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(4 months ago)

US11291645 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(4 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) May 31, 2026
New Patient Population (NPP) Nov 19, 2024
New Strength (NS) Apr 28, 2024

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage

INJECTAFER family patents

Family Patents

19. Isentress patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(4 months ago)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents

20. Juluca patents expiration

JULUCA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(10 months ago)

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage

JULUCA family patents

Family Patents

21. Kombiglyze Xr patents expiration

KOMBIGLYZE XR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(6 months ago)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 05 November, 2010

Treatment: Method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellit...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of KOMBIGLYZE XR before it's drug patent expiration?
More Information on Dosage

KOMBIGLYZE XR family patents

Family Patents

22. Kynamro patents expiration

KYNAMRO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7015315 KASTLE THERAPS LLC Gapped oligonucleotides
Mar, 2023

(11 months ago)

US7101993 KASTLE THERAPS LLC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(5 months ago)

Drugs and Companies using MIPOMERSEN SODIUM ingredient

Market Authorisation Date: 29 January, 2013

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

KYNAMRO family patents

Family Patents

23. Latisse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8038988 ALLERGAN Method of enhancing hair growth
Aug, 2023

(6 months ago)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness

Dosage: SOLUTION/DROPS;TOPICAL

How can I launch a generic of LATISSE before it's drug patent expiration?
More Information on Dosage

LATISSE family patents

Family Patents

24. Leqvio patents expiration

LEQVIO's oppositions filed in EPO
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(1 year, 6 days ago)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(3 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 2025-12-22

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

LEQVIO family patents

Family Patents

25. Mektovi patents expiration

MEKTOVI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178693 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Oct 11, 2026

Drugs and Companies using BINIMETINIB ingredient

Market Authorisation Date: 27 June, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage

MEKTOVI family patents

Family Patents

26. Myrbetriq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(3 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage

MYRBETRIQ family patents

Family Patents

27. Myrbetriq Granules patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(3 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 25 March, 2021

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

MYRBETRIQ GRANULES family patents

Family Patents

28. Nuvigil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7132570 CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Dec, 2023

(2 months ago)

Drugs and Companies using ARMODAFINIL ingredient

Market Authorisation Date: 15 June, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of NUVIGIL before it's drug patent expiration?
More Information on Dosage

NUVIGIL family patents

Family Patents

29. Nuzyra patents expiration

Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326696 PARATEK PHARMS INC Amino-methyl substituted tetracycline compounds
Sep, 2023

(5 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN) Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 2027-10-03

Market Authorisation Date: 02 October, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

NUZYRA family patents

Family Patents

30. Odefsey patents expiration

ODEFSEY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080551 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2023

(10 months ago)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 01 March, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage

ODEFSEY family patents

Family Patents

31. Onglyza patents expiration

ONGLYZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(6 months ago)

Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: Method for treating type ii diabetes by administering saxagliptin; Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazol...

Dosage: TABLET;ORAL

How can I launch a generic of ONGLYZA before it's drug patent expiration?
More Information on Dosage

ONGLYZA family patents

Family Patents

32. Otezla patents expiration

OTEZLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7893101 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Dec, 2023

(2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 19, 2026
New Indication (I) Dec 20, 2024
M (M) Jul 20, 2026

Drugs and Companies using APREMILAST ingredient

Market Authorisation Date: 21 March, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of OTEZLA before it's drug patent expiration?
More Information on Dosage

OTEZLA family patents

Family Patents

33. Prestalia patents expiration

PRESTALIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6696481 ADHERA Salt of perindopril and pharmaceutical compositions containing it
Apr, 2023

(10 months ago)

Drugs and Companies using AMLODIPINE BESYLATE; PERINDOPRIL ARGININE ingredient

Market Authorisation Date: 21 January, 2015

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of PRESTALIA before it's drug patent expiration?
More Information on Dosage

PRESTALIA family patents

Family Patents

34. Qtern patents expiration

QTERN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Strength (NS) May 2, 2022
New Indication (I) May 2, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2017

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of QTERN before it's drug patent expiration?
More Information on Dosage

QTERN family patents

Family Patents

35. Qternmet Xr patents expiration

QTERNMET XR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 2, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

QTERNMET XR family patents

Family Patents

36. Rapivab patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6562861 BIOCRYST Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Dec, 2023

(2 months ago)

Drugs and Companies using PERAMIVIR ingredient

Market Authorisation Date: 19 December, 2014

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

RAPIVAB family patents

Family Patents

37. Rubraca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6495541 CLOVIS ONCOLOGY INC Tricyclic inhibitors of poly(ADP-ribose) polymerases
Nov, 2023

(3 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 6, 2025

Drugs and Companies using RUCAPARIB CAMSYLATE ingredient

Market Authorisation Date: 19 December, 2016

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

RUBRACA family patents

Family Patents

38. Spinraza patents expiration

Can you believe SPINRAZA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7101993 BIOGEN IDEC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(5 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 23, 2023

Drugs and Companies using NUSINERSEN SODIUM ingredient

Market Authorisation Date: 23 December, 2016

Treatment: NA

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

SPINRAZA family patents

Family Patents

39. Stiolto Respimat patents expiration

STIOLTO RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(3 months ago)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(2 months ago)

Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 21 May, 2015

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STIOLTO RESPIMAT family patents

Family Patents

40. Striverdi Respimat patents expiration

STRIVERDI RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(3 months ago)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(2 months ago)

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2014

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STRIVERDI RESPIMAT family patents

Family Patents

41. Tasigna patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169791 NOVARTIS Inhibitors of tyrosine kinases
Jul, 2023

(7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 23, 2028
Pediatric Exclusivity (PED) Mar 23, 2029

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 29 October, 2007

Treatment: A method for the treatment of leukemias

Dosage: CAPSULE;ORAL

How can I launch a generic of TASIGNA before it's drug patent expiration?
More Information on Dosage

TASIGNA family patents

Family Patents

42. Tegsedi patents expiration

TEGSEDI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7015315 AKCEA THERAPS Gapped oligonucleotides
Mar, 2023

(11 months ago)

US7101993 AKCEA THERAPS Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(5 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 5, 2025

Drugs and Companies using INOTERSEN SODIUM ingredient

Market Authorisation Date: 05 October, 2018

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

TEGSEDI family patents

Family Patents

43. Trelegy Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Sep 9, 2023
New Strength (NS) Sep 9, 2023

Drugs and Companies using FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: Indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; And asthma

Dosage: POWDER;INHALATION

More Information on Dosage

TRELEGY ELLIPTA family patents

Family Patents

44. Tyzeka patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7858594 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(5 months ago)

US7589079 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(5 months ago)

Drugs and Companies using TELBIVUDINE ingredient

Market Authorisation Date: 28 April, 2009

Treatment: Treatment of chronic hepatitis b in adult patients

Dosage: SOLUTION;ORAL

More Information on Dosage

TYZEKA family patents

Family Patents

45. Venlafaxine Besylate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6717015 ALMATICA Venlafaxine besylate
Mar, 2023

(11 months ago)

Drugs and Companies using VENLAFAXINE BESYLATE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Treatment of depression and generalized anxiety disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

VENLAFAXINE BESYLATE family patents

Family Patents

46. Vibativ patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6635618 CUMBERLAND PHARMS Glycopeptide phosphonate derivatives
Sep, 2023

(5 months ago)

Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 September, 2009

Treatment: Method for treating bacterial infection

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

VIBATIV family patents

Family Patents

47. Vizamyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7351401 GE HEALTHCARE Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition
Jan, 2023

(1 year, 1 month ago)

Drugs and Companies using FLUTEMETAMOL F-18 ingredient

Market Authorisation Date: 25 October, 2013

Treatment: Diagnostic radioimaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

VIZAMYL family patents

Family Patents

48. Votrient patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7105530 NOVARTIS Pyrimidineamines as angiogenesis modulators
Oct, 2023

(4 months ago)

Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2009

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

VOTRIENT family patents

Family Patents

49. Vyndaqel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8168663 FOLDRX PHARMS Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
Dec, 2023

(2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2024
Orphan Drug Exclusivity (ODE) May 3, 2026

Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient

NCE-1 date: 2023-05-04

Market Authorisation Date: 03 May, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

VYNDAQEL family patents

Family Patents

50. Vyvanse patents expiration

VYVANSE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 2 days ago)

US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(1 year, 2 days ago)

US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(1 year, 2 days ago)

Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient

Market Authorisation Date: 23 February, 2007

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE;ORAL

How can I launch a generic of VYVANSE before it's drug patent expiration?
More Information on Dosage

VYVANSE family patents

Family Patents

51. Xeljanz patents expiration

XELJANZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Dec 14, 2024

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 06 November, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage

XELJANZ family patents

Family Patents

52. Xeljanz Xr patents expiration

XELJANZ XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6965027 PFIZER Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Dec 14, 2024

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 23 February, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XELJANZ XR before it's drug patent expiration?
More Information on Dosage

XELJANZ XR family patents

Family Patents

53. Xepi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6335447 FERRER INTERNACIONAL Quinolonecarboxylic acid derivatives or salts thereof
Nov, 2023

(3 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 11, 2022

Drugs and Companies using OZENOXACIN ingredient

NCE-1 date: 2021-12-11

Market Authorisation Date: 11 December, 2017

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

XEPI family patents

Family Patents

54. Zykadia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9018204 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 26 days ago)

US8835430 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 26 days ago)

US9416112 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 26 days ago)

US8188276 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 26 days ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 26, 2024

Drugs and Companies using CERITINIB ingredient

Market Authorisation Date: 29 April, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

ZYKADIA family patents

Family Patents

List of large molecules

1. List of Vyrologix large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7666419 NA NA
Feb, 2023

(1 year, 5 days ago)

2. List of Humira large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US6805686 ABBVIE INC. Autoinjector with extendable needle protector shroud
May, 2023

(9 months ago)

US9090689 ABBVIE INC. Use of TNFα inhibitor for treatment of psoriasis
Jul, 2023

(7 months ago)

US9085620 ABBVIE INC. Use of TNFα inhibitor for treatment of psoriatic arthritis
Jul, 2023

(7 months ago)

US9067992 ABBVIE INC. Use of TNFα inhibitor for treatment of psoriatic arthritis
Jul, 2023

(7 months ago)

US8906373 ABBVIE INC. Use of TNF-alpha inhibitor for treatment of psoriasis
Jul, 2023

(7 months ago)

Ingredients: ADALIMUMAB

3. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7070959 REGENERON PHARMACEUTICALS, INC. Modified chimeric polypeptides with improved pharmacokinetic properties
Jun, 2023

(8 months ago)

Ingredients: AFLIBERCEPT

4. List of Krystexxa large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US6783965 NA Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
Jul, 2023

(7 months ago)

Ingredients: PEGLOTICASE

5. List of Lumoxiti large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9580461 NA Method for purifying active polypeptides or immunoconjugates
Aug, 2023

(6 months ago)

Ingredients: MOXETUMOMAB-PASUDOTOX-TDFK

6. List of Adcetris large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7090843 NA Recombinant anti-CD30 antibodies and uses thereof
Aug, 2023

(6 months ago)

Ingredients: BRENTUXIMAB

7. List of Stelara large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US6902734 NA Anti-IL-12 antibodies and compositions thereof
Sep, 2023

(5 months ago)

Ingredients: USTEKINUMAB

8. List of Lucentis large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US6921659 GENENTECH, INC. Protease-deficient cells
Oct, 2023

(4 months ago)

US8383773 GENENTECH, INC. Protein product and method for reducing biomass-biomass interactions
Dec, 2023

(2 months ago)

Ingredients: RANIBIZUMAB

9. List of Kalbitor large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7276480 NA Prevention and reduction of blood loss
Dec, 2023

(2 months ago)

Ingredients: ECALLANTIDE